1-6 of 6
Vijayalakshmi Chandrasekaran
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Efficacy and Safety of Recombinant Erwinia Asparaginase (JZP458) in Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL): Complete Follow-up of the Children's Oncology Group (COG) AALL1931 Study

Luke Maese, Mignon L. Loh, Mi Rim Choi, Tong Lin, Etsuko Aoki, Shirali Agarwal, Vijayalakshmi Chandrasekaran, Yali Liang, Suzette Girgis, Cuiping Chen, Robert Iannone, Lewis B. Silverman, Elizabeth A. Raetz, Rachel E. Rau
Journal: Blood
Blood (2023) 142 (Supplement 1): 1498.
https://doi.org/10.1182/blood-2023-172577
Published: 2023
Journal Articles

Immunogenicity of Recombinant Erwinia asparaginase (JZP458) for Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL)

Luke Maese, Mignon L. Loh, Mi Rim Choi, Yali Liang, Etsuko Aoki, Shane Roller, Tong Lin, Shirali Agarwal, Vijayalakshmi Chandrasekaran, Robert Iannone, Lewis B. Silverman, Elizabeth A. Raetz, Rachel E. Rau
Journal: Blood
Blood (2023) 142 (Supplement 1): 5908.
https://doi.org/10.1182/blood-2023-179533
Published: 2023
Journal Articles

Lower-Intensity CPX-351 + Venetoclax for Patients with Newly Diagnosed Acute Myeloid Leukemia Who Are Unfit for Intensive Chemotherapy: Post Hoc Analysis By Disease Risk Subgroups

Tara L. Lin, Praneeth Baratam, Robert K. Stuart, Roland B. Walter, Eric S. Winer, Stefan Faderl, Vijayalakshmi Chandrasekaran, Divya Chakravarthy, Ronald S. Cheung, Vinod A. Pullarkat
Journal: Blood
Blood (2022) 140 (Supplement 1): 3280–3281.
https://doi.org/10.1182/blood-2022-159635
Published: 2022
Journal Articles

V-FAST Master Trial: Subgroup Analysis of Outcomes with CPX-351 Plus Midostaurin in Adults with Newly Diagnosed Acute Myeloid Leukemia By FLT3 Mutation Type

James McCloskey, Vinod A. Pullarkat, Gabriel N. Mannis, Tara L. Lin, Stephen A Strickland, Amir T. Fathi, Stefan Faderl, Divya Chakravarthy, Yana Lutska, Vijayalakshmi Chandrasekaran, Ronald S. Cheung, Mark J. Levis
Journal: Blood
Blood (2022) 140 (Supplement 1): 3312–3314.
https://doi.org/10.1182/blood-2022-159680
Published: 2022
Journal Articles

Preliminary Results By Age Group of Treatment with CPX-351 Plus Venetoclax in Adults with Newly Diagnosed AML: Subgroup Analysis of the V-FAST Phase 1b Master Trial

Vinod A. Pullarkat, Mark Levis, Gabriel N. Mannis, Stephen A Strickland, Tara L. Lin, Stefan Faderl, Divya Chakravarthy, Vijayalakshmi Chandrasekaran, Ronald S. Cheung, Harry P. Erba
Journal: Blood
Blood (2021) 138 (Supplement 1): 1268.
https://doi.org/10.1182/blood-2021-148054
Published: 2021
Journal Articles

Phase 1b Study of Lower-Dose CPX-351 Plus Venetoclax As First-Line Treatment for Patients with AML Who Are Unfit for Intensive Chemotherapy: Preliminary Safety and Efficacy Results

Geoffrey L. Uy, Vinod A. Pullarkat, Praneeth Baratam, Robert K. Stuart, Stefan Faderl, Vijayalakshmi Chandrasekaran, Qi Wang, Divya Chakravarthy, Ronald S. Cheung, Tara L. Lin
Journal: Blood
Blood (2021) 138 (Supplement 1): 2316.
https://doi.org/10.1182/blood-2021-148455
Published: 2021